Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 7;15(7):11984-95.
doi: 10.3390/ijms150711984.

Association of TNFRSF10D DNA-methylation With the Survival of Melanoma Patients

Affiliations
Free PMC article

Association of TNFRSF10D DNA-methylation With the Survival of Melanoma Patients

Gudrun Ratzinger et al. Int J Mol Sci. .
Free PMC article

Abstract

In this retrospective pilot study, the DNA-methylation status of genes that have been demonstrated to be involved in melanoma carcinogenesis was analyzed in order to identify novel biomarkers for the risk assessment of melanoma patients. We analyzed DNA extracted from punch-biopsies from 68 formalin-fixed paraffin-embedded (FFPE) melanoma specimens. Using MethyLight PCR, we examined 20 genes in specimens from a training set comprising 36 melanoma patients. Selected candidate genes were validated in a test set using FFPE tissue samples from 32 melanoma patients. First, we identified the TNFRSF10D DNA-methylation status (TNFRSF10D methylated vs. unmethylated) as a prognostic marker for overall (p = 0.001) and for relapse-free survival (p = 0.008) in the training set. This finding was confirmed in the independent test set (n = 32; overall survival p = 0.041; relapse-free survival p = 0.012). In a multivariate Cox-regression analysis including all patients, the TNFRSF10D DNA-methylation status remained as the most significant prognostic parameter for overall and relapse-free survival (relative-risk (RR) of death, 4.6 (95% CI: 2.0-11.0; p < 0.001), RR of relapse, 7.2 (95% CI: 2.8-18.3; p < 0.001)). In this study, we demonstrate that TNFRSF10D DNA-methylation analysis of a small tissue-punch from archival FFPE melanoma tissue is a promising approach to provide prognostic information in patients with melanoma.

Figures

Figure 1
Figure 1
Kaplan–Meier survival analysis: (A) the overall survival and (B) relapse-free survival of 68 melanoma patients.

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Garbe C., Peris K., Hauschild A., Saiag P., Middleton M., Spatz A., Grob J.J., Malvehy J., Newton-Bishop J., Stratigos A., et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline—Update 2012. Eur. J. Cancer. 2012;48:2375–2390. doi: 10.1016/j.ejca.2012.06.013. - DOI - PubMed
    1. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., Buzaid A.C., Cochran A.J., Coit D.G., Ding S., et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009;27:6199–6206. - PMC - PubMed
    1. Weinlich G., Eisendle K., Hassler E., Baltaci M., Fritsch P.O., Zelger B. Metallothionein—Overexpression as a highly significant prognostic factor in melanoma: A prospective study on 1270 patients. Br. J. Cancer. 2006;94:835–841. - PMC - PubMed
    1. Jönsson G., Busch C., Knappskog S., Geisler J., Miletic H., Ringnér M., Lillehaug J.R., Borg A., Lønning P.E. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 2010;16:3356–3367. - PubMed
    1. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002;3:415–428. - PubMed

Publication types

Substances

Feedback